Test RSS – JMCM

RSS Feed

0. Dyne Therapeutics June 22, 2026
Dyne Therapeutics shared positive topline results from its Phase 1/2 trial of the investigational drug, zeleciment rostudirsen (also known as DYNE-251), in individuals with Duchenne muscular dystrophy amenable to exon 51 skipping. The study met its primary endpoint, demonstrating a statistically significant increase in dystrophin from baseline at 6 months. Furthermore, the treatment maintained a […]
1. Boston Scientific received U.S. Food and Drug Administration (FDA) 510(k) clearance June 22, 2026
Boston Scientific received U.S. Food and Drug Administration (FDA) 510(k) clearance for the expanded indication of Rezūm™ Water Vapor Therapy, increasing the maximum prostate volume that can be treated with the device from 80 cm3 to 150 cm3 for patients with benign prostatic hyperplasia (BPH). Existing real-world and clinical trial data for Rezūm Therapy demonstrates […]
Study finds flaw in method for key oncology value-based care model June 22, 2026
McKesson and The U.S. Oncology Network find the Enhancing Oncology Model attribution often mislabels cancer episodes — especially oral therapy — threatening value-based care accuracy and accountability.
00. PAPZIMEOS was granted full approval June 22, 2026
PAPZIMEOS was granted full approval by the US Food and Drug Administration (FDA) in August 2025, becoming the first and only approved therapy for the treatment of adults with RRP. Effective April 1, 2026, a new, permanent HCPCS Level II J-code (J3404 - injection, zopapogene imadenovec-drba suspension, per therapeutic dose) will be available for the […]
6. NAMCP VBCC June 22, 2026
NAMCP understands the changing landscape with regard to the delivery of healthcare moving from the traditional fee for service model to more of a focus on value based care and all of the complexities therein. The mission of the VBCC is to help payers and medical directors in their efforts to more effectively and efficiently […]
8. LivaNova June 22, 2026
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, has announced that the journal Brain Stimulation has published two pivotal articles chronicling the unipolar cohort data set for the RECOVER clinical study. The researchers evaluated the safety and efficacy of LivaNova's VNS Therapy™ System and its effectiveness on quality of life and daily function in […]
HHS opens applications for $700M in mental health, addiction funding, with $96M for new STREETS program June 22, 2026
U.S. Department of Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr. has announced over $700 million in newly opened funding opportunities that aim to address mental illness, addiction and homelessness.
4. Gilead Sciences, Inc. June 22, 2026
Gilead Sciences, Inc., a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, announced that the US Food and Drug Administration (FDA) has approved YEZTUGO® (lenacapavir) injection, 463.5 mg/1.5 mL. Click here for full Prescribing Information, including BOXED WARNING. Click here to learn more at YeztugoHCP.com.
Preventing the next pandemic using AI-designed vaccines June 22, 2026
Historically, the vaccine development model has been largely reactive and variant-driven, but the industry is now actively shifting toward proactive and universal vaccinology to get ahead of evolving pathogens.
FDA approves 1st single-dose generic flu drug June 22, 2026
The FDA approved the first generic version of Xofluza (baloxavir marboxil) on June 17, clearing Norwich Pharmaceuticals' single-dose influenza tablet ahead of the 2026-27 flu season.

Goodbye 'ghost rounders,' hello value-based catalysts: The new role for medical directors

22 June 2026

As Trilogy Health Services built up its network of value-based care programs over the last several years, its nursing homes tapped an often-overlooked asset to succeed: Their medical directors. Those physicians have become core to Trilogy's value-based care mission, said Chief Medical Officer Andrew McNamara.

Study finds flaw in method for key oncology value-based care model

22 June 2026

McKesson and The U.S. Oncology Network find the Enhancing Oncology Model attribution often mislabels cancer episodes — especially oral therapy — threatening value-based care accuracy and accountability.

CBO asks for more No Surprises research

22 June 2026

The Congressional Budget Office is calling for more research into the effects of the No Surprises Act amid growing concerns that the law meant to shield consumers from unexpected out-of-network medical bills may actually be raising healthcare spending.

ATA urges Congress to make telehealth flexibilities permanent

22 June 2026

This year Congress extended the Acute Hospital Care at Home waiver for five years and Medicare telehealth flexibilities through 2027. But ATA Action, the policy and legislative advocacy arm of the American Telemedicine Association, wants more.

FDA issues guidance on sharing potential NDA patent information

22 June 2026

The U.S. Food and Drug Administration (FDA) has published draft guidance for applicants for new drug applications (NDAs) and NDA holders on submitting patent information to their NDAs using Form FDA 3542a or Form FDA 3542. The guidance is intended to help applicants and holders submit patent information using the correct form to their NDA and aims to answer commonly asked questions.